---
schema_version: "secwatch.filing_event.v1"
accession: "0001217234-22-000185"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:09:06.351487+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CareDx Q3: Revenue $79.4M (+5%), net loss widens to $16.9M; adj EBITDA loss $2.5M

## Summary
- Revenue $79.4M (+5% YoY); testing services $64.8M, product $7.2M, patient/digital $7.4M.
- Net loss $16.9M ($0.32 per share) vs $11.9M loss ($0.23) in Q3 2021.
- Non-GAAP net loss $3.4M vs non-GAAP income $4.0M; non-GAAP EPS -$0.06 vs +$0.07.
- Adjusted EBITDA loss $2.5M vs gain $4.7M; company targets positive adjusted EBITDA by H1 2023.
- Delivered 46,500 patient test results (+15% YoY); cash $291.3M, no debt.

## SEC filing metadata
- accession: 0001217234-22-000185
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000121723422000185/0001217234-22-000185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000121723422000185/cdna-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001217234-22-000185
- JSON: https://secwatch.observer/filing/0001217234-22-000185.json
- Plain text: https://secwatch.observer/filing/0001217234-22-000185.txt

## Key facts
- Earnings Releases
  CareDx, Inc. reported the third quarter ended September 30, 2022 results: revenue $79.4 million, net income net loss was $16.9 million, EPS $0.32.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $79.4 million
  - Net income: net loss was $16.9 million
  - EPS: $0.32
  - Result: reported results
  source text: with positive adjusted EBITDA by first half of 2023 • Delivered 46,500 patient test results, representing growth of 15% compared to third quarter of 2021 • Achieved revenue of $79.4 million, increasing 5% year-over-year • Sustained strong testing services GAAP gross margin of 73% and non-GAAP gross margin of 74% • Strong balance sheet with $291 million cash, cash
  evidence_url: https://www.sec.gov/Archives/edgar/data/1217234/000121723422000185/0001217234-22-000185-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.